Recommendations,Strength rating
Recommendations,Strength rating
"New 2023 recommendation: Offer adjuvant platinum-based chemotherapy after RNU 
to patients with pT2â€“T4 and/or pN+ disease.",Strong
"New 2023 recommendation: Discuss adjuvant nivolumab with patients unfit 
for, or who declined, platinum-based adjuvant chemotherapy for > pT3 and/or 
pN+ disease after RNU alone or > ypT2 and/or ypN+ disease after neoadjuvant 
chemotherapy, followed by RNU.",Weak
"2022 recommendation: Offer kidney-sparing management to patients with solitary 
kidney and/or impaired renal function, providing that it will not compromise survival. 
This decision will have to be made on a case-by-case basis in consultation with the 
patient.",Strong
"Revised 2023 recommendation: Offer kidney-sparing management to high-risk 
patients with imperative indication on a case-by-case basis, in consultation with the 
patient.",Strong
